What is Stifel Canada’s Estimate for TSE:GUD Q1 Earnings?

Knight Therapeutics Inc. (TSE:GUD) – Equities research analysts at Stifel Canada issued their Q1 2025 earnings estimates for Knight Therapeutics in a report issued on Monday, March 24th. Stifel Canada analyst J. Keywood expects that the company will post earnings per share of $0.03 for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.04 EPS and FY2026 earnings at $0.21 EPS.

Other equities analysts have also issued research reports about the company. Canaccord Genuity Group lowered Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 21st. Stifel Nicolaus lifted their price target on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a report on Tuesday. Finally, Research Capitl raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Knight Therapeutics presently has a consensus rating of “Buy” and an average price target of C$7.48.

Knight Therapeutics Stock Down 0.7 %

Shares of GUD opened at C$6.00 on Thursday. The company has a market capitalization of C$606.90 million, a P/E ratio of -20.03, a PEG ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a one year low of C$5.09 and a one year high of C$6.45. The business’s 50 day simple moving average is C$5.73 and its 200-day simple moving average is C$5.59. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79.

Insider Buying and Selling at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan sold 92,200 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of C$6.15, for a total transaction of C$567,030.00. In the last ninety days, insiders have sold 3,143,300 shares of company stock worth $19,733,740. Insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.